{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:57:04Z","timestamp":1794506224876,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1AG057754"],"award-info":[{"award-number":["RO1AG057754"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 NS077889"],"award-info":[{"award-number":["T32 NS077889"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triggering receptor expressed on myeloid cell-2 (TREM2) is a lipid and lipoprotein binding receptor expressed by cells of myeloid origin. Homozygous TREM2 mutations cause early onset progressive presenile dementia while heterozygous, point mutations triple the risk of Alzheimer\u2019s disease (AD). Although human genetic findings support the notion that loss of TREM2 function exacerbates neurodegeneration, it is not clear whether activation of TREM2 in a disease state would result in therapeutic benefits. To determine the viability of TREM2 activation as a therapeutic strategy, we sought to characterize an agonistic Trem2 antibody (AL002a) and test its efficacy and mechanism of action in an aggressive mouse model of amyloid deposition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To determine whether agonism of Trem2 results in therapeutic benefits, we designed both intracranial and systemic administration studies. 5XFAD mice in the intracranial administration study were assigned to one of two injection groups: AL002a, a Trem2-agonizing antibody, or MOPC, an isotype-matched control antibody. Mice were then subject to a single bilateral intracranial injection into the frontal cortex and hippocampus and euthanized 72 h later. The tissue from the left hemisphere was histologically examined for amyloid-beta and microglia activation, whereas the tissue from the right hemisphere was used for biochemical analyses. Similarly, mice in the systemic administration study were randomized to one of the aforementioned injection groups and the assigned antibody was administered intraperitoneally once a week for 14\u2009weeks. Mice underwent behavioral assessment between the 12- and 14-week timepoints and were euthanized 24 h after their final injection. The tissue from the left hemisphere was used for histological analyses whereas the tissue from the right hemisphere was used for biochemical analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we show that chronic activation of Trem2, in the 5XFAD mouse model of amyloid deposition, leads to reversal of the amyloid-associated gene expression signature, recruitment of microglia to plaques, decreased amyloid deposition, and improvement in spatial learning and novel object recognition memory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings indicate that Trem2 activators may be effective for the treatment of AD and possibly other neurodegenerative disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-020-01915-0","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T11:04:05Z","timestamp":1597403045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition"],"prefix":"10.1186","volume":"17","author":[{"given":"Brittani R.","family":"Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany L.","family":"Sudduth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Weekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherika","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hawthorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Woolums","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-1564","authenticated-orcid":false,"given":"Donna M.","family":"Wilcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"1915_CR1","unstructured":"2020 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement 2020."},{"key":"1915_CR2","doi-asserted-by":"crossref","unstructured":"Karran E, Mercken M, De Strooper B: The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature reviews Drug discovery 2011, 10:698-712.","DOI":"10.1038\/nrd3505"},{"key":"1915_CR3","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Brashear HR. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease. N Engl J Med. 2014;370:1460.","journal-title":"N Engl J Med"},{"key":"1915_CR4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"1915_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer\u2019s disease. N Engl J Med. 2013;368:117\u201327.","journal-title":"N Engl J Med"},{"key":"1915_CR6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med. 2013;368:107\u201316.","journal-title":"N Engl J Med"},{"key":"1915_CR7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell. 2015;160:1061\u201371.","journal-title":"Cell"},{"key":"1915_CR8","doi-asserted-by":"crossref","first-page":"26033","DOI":"10.1074\/jbc.M115.677286","volume":"290","author":"CC Bailey","year":"2015","unstructured":"Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds Apolipoprotein E. J Biol Chem. 2015;290:26033\u201342.","journal-title":"J Biol Chem"},{"key":"1915_CR9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","volume":"91","author":"FL Yeh","year":"2016","unstructured":"Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to Apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91:328\u201340.","journal-title":"Neuron"},{"key":"1915_CR10","doi-asserted-by":"crossref","first-page":"26043","DOI":"10.1074\/jbc.M115.679043","volume":"290","author":"Y Atagi","year":"2015","unstructured":"Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem. 2015;290:26043\u201350.","journal-title":"J Biol Chem"},{"key":"1915_CR11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrn.2016.7","volume":"17","author":"M Colonna","year":"2016","unstructured":"Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17:201\u20137.","journal-title":"Nat Rev Neurosci"},{"key":"1915_CR12","doi-asserted-by":"crossref","unstructured":"Peng Q, Malhotra S, Torchia JA, Kerr WG, Coggeshall KM, Humphrey MB: TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal 2010, 3:ra38.","DOI":"10.1126\/scisignal.2000500"},{"key":"1915_CR13","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.4049\/jimmunol.1102836","volume":"188","author":"K Otero","year":"2012","unstructured":"Otero K, Shinohara M, Zhao H, Cella M, Gilfillan S, Colucci A, Faccio R, Ross FP, Teitelbaum SL, Takayanagi H, Colonna M. TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol. 2012;188:2612\u201321.","journal-title":"J Immunol"},{"key":"1915_CR14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuron.2016.09.016","volume":"92","author":"P Yuan","year":"2016","unstructured":"Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;92:252\u201364.","journal-title":"Neuron"},{"key":"1915_CR15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3892\/mmr.2013.1268","volume":"7","author":"X Gao","year":"2013","unstructured":"Gao X, Dong Y, Liu Z, Niu B. Silencing of triggering receptor expressed on myeloid cells-2 enhances the inflammatory responses of alveolar macrophages to lipopolysaccharide. Mol Med Rep. 2013;7:921\u20136.","journal-title":"Mol Med Rep"},{"key":"1915_CR16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1084\/jem.194.8.1111","volume":"194","author":"A Bouchon","year":"2001","unstructured":"Bouchon A, Hernandez-Munain C, Cella M, Colonna M. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med. 2001;194:1111\u201322.","journal-title":"J Exp Med"},{"key":"1915_CR17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20141732","volume":"212","author":"K Wu","year":"2015","unstructured":"Wu K, Byers DE, Jin X, Agapov E, Alexander-Brett J, Patel AC, Cella M, Gilfilan S, Colonna M, Kober DL, et al. TREM-2 promotes macrophage survival and lung disease after respiratory viral infection. J Exp Med. 2015;212:681\u201397.","journal-title":"J Exp Med"},{"key":"1915_CR18","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1523\/JNEUROSCI.2459-16.2017","volume":"37","author":"H Zheng","year":"2017","unstructured":"Zheng H, Jia L, Liu CC, Rong Z, Zhong L, Yang L, Chen XF, Fryer JD, Wang X, Zhang YW, et al. TREM2 promotes microglial survival by activating Wnt\/beta-catenin pathway. J Neurosci. 2017;37:1772\u201384.","journal-title":"J Neurosci"},{"key":"1915_CR19","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.15252\/embr.201743922","volume":"18","author":"F Mazaheri","year":"2017","unstructured":"Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Trumbach D, Wurst W, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18:1186\u201398.","journal-title":"EMBO Rep"},{"key":"1915_CR20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1083\/jcb.200808080","volume":"184","author":"EN N'Diaye","year":"2009","unstructured":"N'Diaye EN, Branda CS, Branda SS, Nevarez L, Colonna M, Lowell C, Hamerman JA, Seaman WE. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol. 2009;184:215\u201323.","journal-title":"J Cell Biol"},{"key":"1915_CR21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.yexmp.2007.11.004","volume":"84","author":"LC Chen","year":"2008","unstructured":"Chen LC, Laskin JD, Gordon MK, Laskin DL. Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia. Exp Mol Pathol. 2008;84:145\u201355.","journal-title":"Exp Mol Pathol"},{"key":"1915_CR22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1084\/jem.20022220","volume":"198","author":"M Cella","year":"2003","unstructured":"Cella M, Buonsanti C, Strader C, Kondo T, Salmaggi A, Colonna M. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med. 2003;198:645\u201351.","journal-title":"J Exp Med"},{"key":"1915_CR23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1046\/j.1471-4159.2002.01243.x","volume":"83","author":"CD Schmid","year":"2002","unstructured":"Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, Sutcliffe JG, Carson MJ. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem. 2002;83:1309\u201320.","journal-title":"J Neurochem"},{"key":"1915_CR24","doi-asserted-by":"crossref","first-page":"E194","DOI":"10.1002\/humu.20836","volume":"29","author":"E Chouery","year":"2008","unstructured":"Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, Megarbane A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat. 2008;29:E194\u2013204.","journal-title":"Hum Mutat"},{"key":"1915_CR25","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1212\/01.WNL.0000160304.00003.CA","volume":"64","author":"HH Klunemann","year":"2005","unstructured":"Klunemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE, et al. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 2005;64:1502\u20137.","journal-title":"Neurology"},{"key":"1915_CR26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaneurol.2013.579","volume":"70","author":"RJ Guerreiro","year":"2013","unstructured":"Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70:78\u201384.","journal-title":"JAMA Neurol"},{"key":"1915_CR27","doi-asserted-by":"crossref","first-page":"243ra286","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra286.","journal-title":"Sci Transl Med"},{"key":"1915_CR28","first-page":"1565","volume":"369","author":"P Rajagopalan","year":"2013","unstructured":"Rajagopalan P, Hibar DP, Thompson PM. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369:1565\u20137.","journal-title":"N Engl J Med"},{"key":"1915_CR29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuron.2013.02.026","volume":"78","author":"C Cruchaga","year":"2013","unstructured":"Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer\u2019s disease. Neuron. 2013;78:256\u201368.","journal-title":"Neuron"},{"key":"1915_CR30","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.neurobiolaging.2014.06.007","volume":"35","author":"EO Luis","year":"2014","unstructured":"Luis EO, Ortega-Cubero S, Lamet I, Razquin C, Cruchaga C, Benitez BA, Lorenzo E, Irigoyen J. Alzheimer's Disease Neuroimaging I, Pastor MA, Pastor P: Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. Neurobiol Aging. 2014;35:2681\u201390.","journal-title":"Neurobiol Aging"},{"key":"1915_CR31","doi-asserted-by":"crossref","first-page":"222 e229","DOI":"10.1016\/j.neurobiolaging.2016.07.028","volume":"48","author":"C Pottier","year":"2016","unstructured":"Pottier C, Ravenscroft TA, Brown PH, Finch NA, Baker M, Parsons M, Asmann YW, Ren Y, Christopher E, Levitch D, et al. TYROBP genetic variants in early-onset Alzheimer\u2019s disease. Neurobiol Aging. 2016;48:222 e229\u201315.","journal-title":"Neurobiol Aging"},{"key":"1915_CR32","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1038\/ncomms7176","volume":"6","author":"C Condello","year":"2015","unstructured":"Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat Commun. 2015;6:6176.","journal-title":"Nat Commun"},{"key":"1915_CR33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.molmed.2017.03.008","volume":"23","author":"FL Yeh","year":"2017","unstructured":"Yeh FL, Hansen DV, Sheng M. TREM2, microglia, and neurodegenerative diseases. Trends Mol Med. 2017;23:512\u201333.","journal-title":"Trends Mol Med"},{"key":"1915_CR34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.20142322","volume":"212","author":"TR Jay","year":"2015","unstructured":"Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer\u2019s disease mouse models. J Exp Med. 2015;212:287\u201395.","journal-title":"J Exp Med"},{"key":"1915_CR35","doi-asserted-by":"crossref","first-page":"992","DOI":"10.15252\/emmm.201606370","volume":"8","author":"X Xiang","year":"2016","unstructured":"Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med. 2016;8:992\u20131004.","journal-title":"EMBO Mol Med"},{"key":"1915_CR36","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169:1276\u20131290 e1217.","journal-title":"Cell"},{"key":"1915_CR37","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","volume":"80","author":"CM Roe","year":"2013","unstructured":"Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TL, Mintun MA, Holtzman DM, Morris JC. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5\u2009years later. Neurology. 2013;80:1784\u201391.","journal-title":"Neurology"},{"key":"1915_CR38","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129\u201340.","journal-title":"J Neurosci"},{"key":"1915_CR39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1089\/10445490152717596","volume":"20","author":"DM Wilcock","year":"2001","unstructured":"Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, et al. Number of Abeta inoculations in APP + PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 2001;20:731\u20136.","journal-title":"DNA Cell Biol"},{"key":"1915_CR40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/alzrt262","volume":"6","author":"TL Sudduth","year":"2014","unstructured":"Sudduth TL, Weekman EM, Brothers HM, Braun K, Wilcock DM. Beta-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP\/PS1 transgenic mice. Alzheimers Res Ther. 2014;6:32.","journal-title":"Alzheimers Res Ther"},{"key":"1915_CR41","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/nprot.2006.275","volume":"1","author":"J Alamed","year":"2006","unstructured":"Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1:1671\u20139.","journal-title":"Nat Protoc"},{"key":"1915_CR42","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1523\/JNEUROSCI.23-09-03745.2003","volume":"23","author":"DM Wilcock","year":"2003","unstructured":"Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745\u201351.","journal-title":"J Neurosci"},{"key":"1915_CR43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3389\/fnbeh.2015.00183","volume":"9","author":"R Blaser","year":"2015","unstructured":"Blaser R, Heyser C. Spontaneous object recognition: a promising approach to the comparative study of memory. Front Behav Neurosci. 2015;9:183.","journal-title":"Front Behav Neurosci"},{"key":"1915_CR44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","volume":"52","author":"R Dodel","year":"2002","unstructured":"Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Hoft C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer\u2019s disease. Ann Neurol. 2002;52:253\u20136.","journal-title":"Ann Neurol"},{"key":"1915_CR45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/clpt.2010.165","volume":"88","author":"MD Carter","year":"2010","unstructured":"Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer\u2019s disease. Clin Pharmacol Ther. 2010;88:475\u201386.","journal-title":"Clin Pharmacol Ther"},{"key":"1915_CR46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pharmthera.2012.07.001","volume":"136","author":"DS Himmelstein","year":"2012","unstructured":"Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI. Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther. 2012;136:8\u201322.","journal-title":"Pharmacol Ther"},{"key":"1915_CR47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrneurol.2017.61","volume":"13","author":"LG Apostolova","year":"2017","unstructured":"Apostolova LG. Alzheimer disease: a quantitative trait approach to GWAS pays dividends. Nat Rev Neurol. 2017;13:321\u20132.","journal-title":"Nat Rev Neurol"},{"key":"1915_CR48","doi-asserted-by":"crossref","unstructured":"Schlepckow K, Monroe KM, Kleinberger G, Cantuti-Castelvetri L, Parhizkar S, Xia D, Willem M, Werner G, Pettkus N, Brunner B, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020:e11227.","DOI":"10.15252\/emmm.201911227"},{"key":"1915_CR49","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0197-4580(01)00292-5","volume":"22","author":"G DiCarlo","year":"2001","unstructured":"DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP + PS1 transgenic mice. Neurobiol Aging. 2001;22:1007\u201312.","journal-title":"Neurobiol Aging"},{"key":"1915_CR50","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","volume":"24","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144\u201351.","journal-title":"J Neurosci"},{"key":"1915_CR51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbd.2003.09.015","volume":"15","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis. 2004;15:11\u201320.","journal-title":"Neurobiol Dis"},{"key":"1915_CR52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.jnen.0000178444.33972.e0","volume":"64","author":"D Morgan","year":"2005","unstructured":"Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol. 2005;64:743\u201353.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1915_CR53","doi-asserted-by":"crossref","unstructured":"Wilcock DM, Zhao Q, Morgan D, Gordon MN, Everhart A, Wilson JG, Lee JE, Colton CA: Diverse inflammatory responses in transgenic mouse models of AD and the effect of immunotherapy on these responses. ASN neuro 2011.","DOI":"10.1042\/AN20110018"},{"key":"1915_CR54","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1523\/JNEUROSCI.0299-11.2011","volume":"31","author":"G Naert","year":"2011","unstructured":"Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer\u2019s disease. J Neurosci. 2011;31:6208\u201320.","journal-title":"J Neurosci"},{"key":"1915_CR55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3233\/JAD-2008-14203","volume":"14","author":"M Reale","year":"2008","unstructured":"Reale M, Iarlori C, Feliciani C, Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer\u2019s disease. J Alzheimers Dis. 2008;14:147\u201359.","journal-title":"J Alzheimers Dis"},{"key":"1915_CR56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.it.2014.04.002","volume":"35","author":"YY Wan","year":"2014","unstructured":"Wan YY. GATA3: a master of many trades in immune regulation. Trends Immunol. 2014;35:233\u201342.","journal-title":"Trends Immunol"},{"key":"1915_CR57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40035-016-0054-4","volume":"5","author":"C Zheng","year":"2016","unstructured":"Zheng C, Zhou XW, Wang JZ. The dual roles of cytokines in Alzheimer\u2019s disease: update on interleukins, TNF-alpha TGF-beta and IFN-gamma. Transl Neurodegener. 2016;5:7.","journal-title":"Transl Neurodegener"},{"key":"1915_CR58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.nbd.2014.05.018","volume":"69","author":"F Rivera-Escalera","year":"2014","unstructured":"Rivera-Escalera F, Matousek SB, Ghosh S, Olschowka JA, O\u2019Banion MK. Interleukin-1beta mediated amyloid plaque clearance is independent of CCR2 signaling in the APP\/PS1 mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2014;69:124\u201333.","journal-title":"Neurobiol Dis"},{"key":"1915_CR59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.neuron.2014.12.068","volume":"85","author":"MV Guillot-Sestier","year":"2015","unstructured":"Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J Jr, Leung BP, Rezai-Zadeh K, Town T. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron. 2015;85:534\u201348.","journal-title":"Neuron"},{"key":"1915_CR60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.expneurol.2004.07.007","volume":"190","author":"DL Herber","year":"2004","unstructured":"Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, Gordon MN. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol. 2004;190:245\u201353.","journal-title":"Exp Neurol"},{"key":"1915_CR61","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.neuron.2014.11.020","volume":"85","author":"P Chakrabarty","year":"2015","unstructured":"Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85:519\u201333.","journal-title":"Neuron"},{"key":"1915_CR62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031993","volume":"7","author":"TL Sudduth","year":"2012","unstructured":"Sudduth TL, Wilson JG, Everhart A, Colton CA, Wilcock DM. Lithium treatment of APPSwDI\/NOS2-\/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PloS one. 2012;7:e31993.","journal-title":"PloS one"},{"key":"1915_CR63","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/ilar\/ilu013","volume":"55","author":"CV Vorhees","year":"2014","unstructured":"Vorhees CV, Williams MT. Assessing spatial learning and memory in rodents. ILAR J. 2014;55:310\u201332.","journal-title":"ILAR J"},{"key":"1915_CR64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ntt.2014.07.003","volume":"45","author":"CV Vorhees","year":"2014","unstructured":"Vorhees CV, Williams MT. Value of water mazes for assessing spatial and egocentric learning and memory in rodent basic research and regulatory studies. Neurotoxicol Teratol. 2014;45:75\u201390.","journal-title":"Neurotoxicol Teratol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01915-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-020-01915-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01915-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T18:45:38Z","timestamp":1667760338000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-020-01915-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1915"],"URL":"https:\/\/doi.org\/10.1186\/s12974-020-01915-0","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"7 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures conformed to the National Institutes of Health Guide for the Care and Use of Animals in Research and were approved by the University of Kentucky Institutional Animal Care and Use Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Wilcock has been a paid consultant of Alector. Data for Fig.\n                      \n                      were generated by scientists at Alector.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}